Multimodality treatment with radiotherapy for huge hepatocellular carcinoma

Hee Ji Han, Mi Sun Kim, Jihye Cha, Jin Sub Choi, Kwang Hyub Han, Jinsil Seong

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background: For huge hepatocellular carcinoma (HCC), therapeutic decisions have varied from local therapy to systemic therapy, with radiotherapy (RT) playing only a palliative role. In this study, we investigated whether multimodality treatment involving RT could be effective in huge HCC. Results: This study was performed in 116 patients with HCC >10 cm. The number of patients in stage II, III and IV was 12, 54 and 50, respectively. RT was given as a combined modality in most patients. The median dose was 45 Gy, with 1.8 Gy per fraction. The median overall survival (OS) and progression-free survival (PFS) were 14.8 and 6.5 months, respectively. The median infield PFS was not reached. Infield failure, outfield intrahepatic and extrahepatic failure were observed in 8.6, 18.1, and 12.1% of patients, respectively. For OS and PFS, number of tumors, initial alpha-fetoprotein (AFP) level, treatment response, percent AFP decrement, and hepatic resection were significant prognostic factors. Tumor characteristics and treatment response were significantly different between long-term survivors and the other patients. Conclusion: Although huge HCC presents an aggressive clinical course, multimodality approaches involving RT can offer an opportunity for prolonged survival.

Original languageEnglish
Pages (from-to)82-89
Number of pages8
JournalOncology (Switzerland)
Volume87
DOIs
Publication statusPublished - 2014 Apr 20

Fingerprint

Hepatocellular Carcinoma
Radiotherapy
Disease-Free Survival
alpha-Fetoproteins
Survival
Therapeutics
Survivors
Neoplasms
Liver

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Han, Hee Ji ; Kim, Mi Sun ; Cha, Jihye ; Choi, Jin Sub ; Han, Kwang Hyub ; Seong, Jinsil. / Multimodality treatment with radiotherapy for huge hepatocellular carcinoma. In: Oncology (Switzerland). 2014 ; Vol. 87. pp. 82-89.
@article{9b00c636f63a4dc694b854711fe772bb,
title = "Multimodality treatment with radiotherapy for huge hepatocellular carcinoma",
abstract = "Background: For huge hepatocellular carcinoma (HCC), therapeutic decisions have varied from local therapy to systemic therapy, with radiotherapy (RT) playing only a palliative role. In this study, we investigated whether multimodality treatment involving RT could be effective in huge HCC. Results: This study was performed in 116 patients with HCC >10 cm. The number of patients in stage II, III and IV was 12, 54 and 50, respectively. RT was given as a combined modality in most patients. The median dose was 45 Gy, with 1.8 Gy per fraction. The median overall survival (OS) and progression-free survival (PFS) were 14.8 and 6.5 months, respectively. The median infield PFS was not reached. Infield failure, outfield intrahepatic and extrahepatic failure were observed in 8.6, 18.1, and 12.1{\%} of patients, respectively. For OS and PFS, number of tumors, initial alpha-fetoprotein (AFP) level, treatment response, percent AFP decrement, and hepatic resection were significant prognostic factors. Tumor characteristics and treatment response were significantly different between long-term survivors and the other patients. Conclusion: Although huge HCC presents an aggressive clinical course, multimodality approaches involving RT can offer an opportunity for prolonged survival.",
author = "Han, {Hee Ji} and Kim, {Mi Sun} and Jihye Cha and Choi, {Jin Sub} and Han, {Kwang Hyub} and Jinsil Seong",
year = "2014",
month = "4",
day = "20",
doi = "10.1159/000368150",
language = "English",
volume = "87",
pages = "82--89",
journal = "Oncology",
issn = "0030-2414",
publisher = "S. Karger AG",

}

Multimodality treatment with radiotherapy for huge hepatocellular carcinoma. / Han, Hee Ji; Kim, Mi Sun; Cha, Jihye; Choi, Jin Sub; Han, Kwang Hyub; Seong, Jinsil.

In: Oncology (Switzerland), Vol. 87, 20.04.2014, p. 82-89.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Multimodality treatment with radiotherapy for huge hepatocellular carcinoma

AU - Han, Hee Ji

AU - Kim, Mi Sun

AU - Cha, Jihye

AU - Choi, Jin Sub

AU - Han, Kwang Hyub

AU - Seong, Jinsil

PY - 2014/4/20

Y1 - 2014/4/20

N2 - Background: For huge hepatocellular carcinoma (HCC), therapeutic decisions have varied from local therapy to systemic therapy, with radiotherapy (RT) playing only a palliative role. In this study, we investigated whether multimodality treatment involving RT could be effective in huge HCC. Results: This study was performed in 116 patients with HCC >10 cm. The number of patients in stage II, III and IV was 12, 54 and 50, respectively. RT was given as a combined modality in most patients. The median dose was 45 Gy, with 1.8 Gy per fraction. The median overall survival (OS) and progression-free survival (PFS) were 14.8 and 6.5 months, respectively. The median infield PFS was not reached. Infield failure, outfield intrahepatic and extrahepatic failure were observed in 8.6, 18.1, and 12.1% of patients, respectively. For OS and PFS, number of tumors, initial alpha-fetoprotein (AFP) level, treatment response, percent AFP decrement, and hepatic resection were significant prognostic factors. Tumor characteristics and treatment response were significantly different between long-term survivors and the other patients. Conclusion: Although huge HCC presents an aggressive clinical course, multimodality approaches involving RT can offer an opportunity for prolonged survival.

AB - Background: For huge hepatocellular carcinoma (HCC), therapeutic decisions have varied from local therapy to systemic therapy, with radiotherapy (RT) playing only a palliative role. In this study, we investigated whether multimodality treatment involving RT could be effective in huge HCC. Results: This study was performed in 116 patients with HCC >10 cm. The number of patients in stage II, III and IV was 12, 54 and 50, respectively. RT was given as a combined modality in most patients. The median dose was 45 Gy, with 1.8 Gy per fraction. The median overall survival (OS) and progression-free survival (PFS) were 14.8 and 6.5 months, respectively. The median infield PFS was not reached. Infield failure, outfield intrahepatic and extrahepatic failure were observed in 8.6, 18.1, and 12.1% of patients, respectively. For OS and PFS, number of tumors, initial alpha-fetoprotein (AFP) level, treatment response, percent AFP decrement, and hepatic resection were significant prognostic factors. Tumor characteristics and treatment response were significantly different between long-term survivors and the other patients. Conclusion: Although huge HCC presents an aggressive clinical course, multimodality approaches involving RT can offer an opportunity for prolonged survival.

UR - http://www.scopus.com/inward/record.url?scp=84922480238&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84922480238&partnerID=8YFLogxK

U2 - 10.1159/000368150

DO - 10.1159/000368150

M3 - Article

C2 - 25427738

AN - SCOPUS:84922480238

VL - 87

SP - 82

EP - 89

JO - Oncology

JF - Oncology

SN - 0030-2414

ER -